Novo Nordisk A/S (ADR) (NVO)
Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals.
Recs
JChief
(36.53)
Submitted: 11/1/2009 1:13:34 AM :
Start Price:
$61.81
NVO Score:
+1.51
Ran the numbers and feel good about it long term.
Recs
mbhoch
(< 20)
Submitted: 10/14/2009 12:55:16 AM :
Start Price:
$64.17
NVO Score:
+2.76
Novo has practically no debt whatsoever, over 20% profit margin and has good niche. They don't have a lot of competitors and they have an international reach with their products. They also pay a $0.74 dividend. The only thing I see as a problem is the high P/E ratio, they're trading well above their worth right now. So if you are a growth or value investor, this probably isn't a good buy right now, but a great stock for stability and income.
Recs
wishlist3410
(< 20)
Submitted: 10/13/2009 4:36:23 PM :
Start Price:
$64.17
NVO Score:
+2.76
Diabetes is an every growing problem in our society. People still continue to eat what they want.
Recs
5SsmallcapDIV
(68.19)
Submitted: 9/2/2009 3:55:38 PM :
Start Price:
$60.21
NVO Score:
+0.38
5 Star, Small Cap- pays dividend
Recs
EBStroke
(< 20)
Submitted: 8/15/2009 8:35:12 PM :
Start Price:
$62.30
NVO Score:
+2.54
Zacks Rank 1, Recommend Neutral, Industry Rank 86 / 217, Target 62.30, Avg target of 7 analysts 65.60
Recs
ingarf
(71.19)
Submitted: 7/30/2009 4:24:02 PM :
Start Price:
$58.47
NVO Score:
+2.24
Long term Buy and Hold. Main focus of Novo Nordisk is diabetes care. With our lifestyle this is an increasing market whatever happens with the recession.
Recs
minnmex
(64.84)
Submitted: 7/24/2009 3:07:44 PM :
Start Price:
$58.32
NVO Score:
+1.45
Dividend payout and low Debt-Equity make it a good play in the medical sector
Recs
georcole
(85.12)
Submitted: 7/10/2009 10:48:04 PM :
Start Price:
$53.21
NVO Score:
+0.19
With food companies putting more sugar in a lot of our foods, diabetes is going to become a bigger problem than it is today. No matter what the economy does, people will still need to get their insulin and such, and Novo Nordisk is in a great position to capitalize on this unfortunate situation. They have grown at a pretty good clip and are sure to continue into the foreseeable future. I do not consider them a cheap stock, but I do see them as undervalued. And as revenue grows, so will their share price.
Recs
keith134
(36.88)
Submitted: 7/4/2009 9:19:51 PM :
Start Price:
$54.16
NVO Score:
-1.11
a great Dansih insulin producer which shouid make for a great long term buy and hold investment.
Recs
TRGoodvsEvil
(< 20)
Submitted: 7/4/2009 12:34:47 AM :
Start Price:
$54.16
NVO Score:
-1.11
2009 World's Most Ethical Companies:
http://ethisphere.com/wme2009/
Recs
indyjoneses
(99.43)
Submitted: 5/28/2009 10:12:20 AM :
Start Price:
$50.88
NVO Score:
+6.67
Great play in a diabetes-focused pharamceutical company. As the general population ages, they will do better and better.
Recs
Izznogood
(44.37)
Submitted: 4/28/2009 3:29:52 PM :
Start Price:
$46.97
NVO Score:
+12.48
Steady, innovative, well run company with a clear business focus in a growing market
Recs
mtinvest
(27.84)
Submitted: 3/25/2009 6:30:16 PM :
Start Price:
$51.00
NVO Score:
-4.33
World leader in insulin. Unfortunately not fewer fat people on the planet in the future.
Recs
Turbolover
(78.51)
Submitted: 3/22/2009 4:02:20 AM :
Start Price:
$45.84
NVO Score:
+4.33
This one falls under the Fool Rule of investing in what you know. Sadly, diabetes is a growth industry, and Novo Nordisk has great name recognition. When I was diagnosed with type II diabetes, I instantly recalled the Novo Nordisk commercials from NPR.
Most diabetes related companies seem to focus on delivery systems for insulin. With Type II diabetes rates skyrocketing, current research will pay off in the long term.
My endocrinologist, who is a researcher, told me about a movement to LOWER the blood sugar levels considered to be diabetic. This would cast a wider net and a substantially higher percentage of the population would then require treatment.
Recs
RugbyViking13
(90.33)
Submitted: 2/26/2009 2:21:08 PM :
Start Price:
$50.34
NVO Score:
-12.54
cause people just keep getting fatter and diabetes is going to be an epidemic
Recs
AndyKane
(< 20)
Submitted: 1/31/2009 12:03:45 PM :
Start Price:
$52.85
NVO Score:
-11.08
-Its sad, but aging baby boomers equals more diabetes patients
-Large cash position provides protection from credit issues that will continue to hurt the overall market...while the overall market is focused on improving its balance sheet, NVO can use its money to improve its business through continued investment in developing new products and getting them approved
Recs
Tutom
(< 20)
Submitted: 1/13/2009 2:23:59 PM :
Start Price:
$52.02
NVO Score:
-1.25
Diabetes: Clearly a disease on the increase.
Recs
Recs
WPThatcher
(41.44)
Submitted: 12/10/2008 1:31:58 PM :
Start Price:
$49.63
NVO Score:
+8.91
Cash rich.
Recs
Tuusa
(< 20)
Submitted: 11/13/2008 2:04:15 PM :
Start Price:
$47.93
NVO Score:
+6.64
With an ever increasing number of people becoming diabetic, this company is in a very good position to have an impact. Diabetes is a world wide issue that will continue to grow (albeit unfortunately) into the future. Novo Nordisk is set as a solid foundation for future growth.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 65 1 2 3 4 Next »